The work

You will review patient charts for signs of transthyretin (ATTR) cardiac amyloidosis, assign consistent case labels, and document the evidence supporting each assessment. Records may be incomplete, so the work requires separating documented facts from reasonable inferences, recognizing relevant history and diagnostic findings such as PYP scan results, and distinguishing ATTR from competing explanations.

What the platform screens for

The screening is likely to test specific experience in cardiology, heart failure, and suspected or confirmed ATTR cardiomyopathy. Expect follow-up questions about how you interpret evidence within your professional scope, handle uncertainty, apply repeatable labeling criteria, revise an assessment when new information appears, and explain clinical decisions to technical teams. Experience in an amyloidosis center of excellence or cardiomyopathy clinic, ATTR research or publications, AI or ML collaboration, clinical decision support, or chart abstraction is preferred rather than required.

Practical details

The engagement is part-time and limited to US-based clinicians, with an expected commitment of 10–20 hours per week alongside clinical practice. The listing does not specify whether the work is remote, fully asynchronous, or tied to fixed working hours, so candidates should confirm scheduling, turnaround expectations, and chart-access arrangements during the process.

Pay band: $80–120/hr